Needle-free intravenous connectors - incompatibility and risk of infection

(All manufacturers) some pre-filled glass syringes are incompatible with some needle-free connectors; and when adaptor stays attached after use there is a possible risk of infection and or air embolus to patients. (MDA/2011/068)

Device

Needle-free intravenous connectors.

All manufacturers.

All models.

All brands of needle-free connectors for vascular access. This includes extension and administration sets with integral connectors.

When the valve is activated by an IV device with a male Luer fitting, such as a syringe (without a needle) or an administration set, the fluid pathway is opened to allow the administration of fluids or aspiration of blood for sampling. Upon removal of the device, the top/septum should automatically return to its closed/home position and seal the fluid pathway. These connectors are not IV caps, bungs or obturators.

Problem

  • Incompatibility of some pre-filled glass syringes with various needle-free connectors
  • Possible risk of infection and/or air embolus to patients when an adaptor remains attached to a needle-free connector after use

The MHRA issued MDA/2004/005 in January 2004 to raise awareness of incompatibility between some needle-free connectors and Luer tips of pre-filled syringes.

The MHRA continues to receive reports of damage to the needle-free connector and/or to the pre-filled syringe where force has been used to connect incompatible devices together. In some cases fragments may block the syringe outflow. Such damage has resulted in a delay in administering therapy during the resuscitation of patients.

The MHRA also continues to receive reports of adverse incidents involving pre-filled glass syringes used with an adaptor which enables compatibility with a needle-free connector. If the adaptor is not removed from the needle-free connector after administration of fluid via an intravenous catheter, the IV pathway remains open. This poses a risk of infection and the potential for air embolus.

Action

  • Ensure procedures are in place to determine the compatibility of needle-free connectors in use with pre-filled syringes contained in emergency drug boxes. Refer to the compatibility warnings and Luer size limits in the instructions for use of the connector. The summary product characteristics (SPC) of the medicine may also include compatibility warnings
  • Follow the advice on page 2 of this alert if they are not compatible
  • Ensure procedures are in place to prevent adaptors being left attached to a needle-free connector after use.

If the needle-free connector is not compatible with the pre-filled syringe:

  • follow any advice given in the instructions for use
  • seek an alternative connector or syringe that is compatible, or
    • use alternative venous access, or
    • in an emergency, consider removing the connector or the extension line possessing
      integral connectors from the intravenous catheter to access the catheter directly
  • ensure adaptors are removed immediately after use.

The MHRA does not hold a list of incompatible devices.

Distribution

This MDA has been sent to:

  • NHS trusts in England (Chief Executives)
  • Care Quality Commission (CQC) (Headquarters) for information
  • HSC trusts in Northern Ireland (Chief Executives)
  • NHS boards in Scotland (Equipment Co-ordinators)
  • Local authorities in Scotland (Equipment Co-ordinators)
  • NHS boards and trusts in Wales (Chief Executives)
  • Primary care trusts in England (Chief Executives)

Onward distribution

Please bring this notice to the attention of relevant employees in your establishment. Below is a suggested list of recipients.

Trusts
CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:

  • A&E departments
  • Adult & paediatric intensive care units
  • All medical and nursing staff
  • All wards and clinical departments
  • Ambulance staff
  • Anaesthesia, directors of
  • Clinical governance leads
  • Health and safety managers
  • Infection prevention nurses
  • IV nurse specialists
  • Medical directors
  • Nursing executive directors
  • Pharmacists
  • Purchasing managers
  • Resuscitation officers and trainers
  • Risk managers
  • Special care baby units
  • Theatre managers

Health Protection Agency
Directors for onward distribution to:

  • Health protection nurses

Primary care trusts
CAS liaison officers for onward distribution to all relevant staff including:

  • Clinical governance leads
  • Community hospitals
  • District nurses

Independent distribution

Establishments registered with the Care Quality Commission (CQC) (England only)
This alert should be read by:

  • Clinics
  • Hospices
  • Hospitals in the independent sector
  • Hospitals in the independent sector
  • Independent treatment centres

Please note: CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health’s Central Alerting System (CAS) by sending an email to: [email protected] and requesting this facility.

Feedback

If you have any comments or feedback on this Medical Device Alert, please email us at: [email protected]

England

If you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2011/068 or 2011/002/025/081/017

Technical aspects

Sharon Knight or Louise Mulroy

Medicines and Healthcare products Regulatory Agency

Floor 4

151 Buckingham Palace Road

London SW1W 9SZ


Tel: 020 3080 7202 / 7344

Fax: 020 8754 3965

Email: [email protected]
[email protected]

Clinical aspects

Jonathan Plumb

Medicines and Healthcare products Regulatory Agency

Floor 4

151 Buckingham Palace Road

London SW1W 9SZ

Tel: 020 3080 7128

Fax: 020 8754 3965

Email: [email protected]

How to report adverse incidents

Please report via the MHRA website

Further information about CAS can be found on the CAS website

Northern Ireland

Alerts in Northern Ireland will continue to be distributed via the NI SABS system.
Enquiries and adverse incident reports in Northern Ireland should be addressed to:

Northern Ireland Adverse Incident Centre

Health Estates Investment Group

Room 17

Annex 6

Castle Buildings

Stormont Estate

Dundonald BT4 3SQ


Tel: 02890 523 704

Fax: 02890 523 900

Email: [email protected]
http://www.dhsspsni.gov.uk/index/hea/niaic.htm

How to report adverse incidents in Northern Ireland

Please report directly to NIAIC, further information can be found on the NIAIC website 

Further information about SABS can be found on the SABS website

Scotland

Enquiries and adverse incident reports in Scotland should be addressed to:

Incident Reporting and Investigation Centre

Health Facilities Scotland

NHS National Services Scotland

Gyle Square

1 South Gyle Crescent

Edinburgh EH12 9EB


Tel: 0131 275 7575

Fax: 0131 314 0722

Email: [email protected]
Incident Reporting and Investigation Centre (IRIC) 

Wales

Enquiries in Wales should be addressed to:

Dr Sara Hayes

Senior Medical Officer

Medical Device Alerts

Welsh Assembly Government

Cathays Park

Cardiff CF10 3NQ


Tel: 029 2082 3922

Email: [email protected]

Download documents

Medical Device Alert: Needle-free intravenous connectors (MDA/2011/068) (402Kb)

Updates to this page

Published 17 December 2014